medigraphic.com

2003, Number 1

Next >>

Arch Cardiol Mex 2003; 73 (1)

Fibrinogen as risk factor

Izaguirre ÁR, Zaldívar AH

Language: Spanish
References: 36
Page: 7-10
PDF size: 56.10 Kb.


Text Extraction

No abstract


REFERENCES

  1. Green FR: Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 2001; 936: 549-559.

  2. Thomas AE, Green FR, Kelleher CH, Wilkesb HC, Brennan PJ, Meade TW, et al: Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and no-smokers. Thromb Haemost 1991; 65: 487-490.

  3. Iacoviello L, Vischetti M, Zito F, Benedetta M: Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199-1203.

  4. Humphries SE, Loung LA, Montgomery HE, Day I, Mohamed V, Yudkin J: Gene-environment interaction in the determinations of levels of plasma fibrinogen. Thromb Haemost 1999; 82: 818-825.

  5. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE: Interleukin-6-174G > C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22: 599-604.

  6. Fenf D, Lindpaintner K, Larson MG, O’Donnell CJ, Lipinska I, Sutherland PA, et al: Platelet gycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Stuply. Circulation 2001; 104: 140-144.

  7. Izaguirre R, Ruiz de Chávez A, Villavicencio R, Gómez A, Mar R, Spíndola C, Casanova J: Variaciones en la hemostasia y fibrinólisis durante el tratamiento del infarto agudo del miocardio con activador tisular del plasminógeno. Arch Inst Cardiol Mex 1993; 63: 235-240.

  8. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, et al: Acute coronary reocclusion after thrombolysis with recombinant tissue-type plasminogen activator. Prevention by maintenance infusion. Circulation 1986; 73: 347-352.

  9. Smith E, Keen GA, Grant A: Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-275.

  10. Otto C, Richter WO, Schwandt P: Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and hypertriglyceridemia: evaluation by selective depletion of low-density lipoproteins or fibrinogen. Metabolism 2000; 49: 810-813.

  11. Tataru MC, Schulte H, Von Eckardstein A, Heinrich J, Assmann G, Koehler E: Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Coron Artery Dis 2001; 12: 157-165.

  12. Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E: Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheal arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-1920.

  13. Montalescot G, Collet JP, Choussat R, Thomas D: Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19: H11-H17.

  14. Wilhemsen L, Svardsudd K, Korsan K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.

  15. Qizilbash N, Jones L, Warlow C, Mann J: Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. Br J Med L 1991; 303: 605-609.

  16. Bainton D, Sweetnam P, Baker I, Elwood P: Peripheal vascular disease. Consequence for survival and association with risk factors in the Speedwell Prospective Heart Disease Study. Br Heart J 1994; 72: 128-132.

  17. Colas JL, Montalescot G, Tribouilloy C: Fibrinogen: a cardiovascular risk factor. Presse Med 2000; 29: 1862-1866.

  18. Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, et al: Haemostatic function and cardiovascular death: Early results of a Prospective study. Lancet 1980; 1: 1050-1054.

  19. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al: Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.

  20. Ernst E, Resch K: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.

  21. Danesh J, Collins R, Appleby P, Peto R: Fibrinogen, C-reactive protein, albumin or white cell count: meta-analyses of prospective sudies of coronary heart disease. JAMA 1998; 279: 1477-1482.

  22. Maresca G, Di Blasio A, Marchili R, Di Minno G: Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.

  23. Acevedo M, Foody JM, Pearce GL, Sprecher DL: Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J 2002; 143: 277-282.

  24. Izaguirre R, De la Peña A, Barinagarrementería F, González H, Ramírez AE, Ruiz JL, et al: Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002; 8: 1169-177.

  25. Ma J, Hennekens C, Ridker P, Stumpfer M. A Prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol 1999; 33: 1347-1352.

  26. Roeters JE, Westerveld HT, Erkelens DW, Van Der Wall E: Risk factors for coronary heart disease: implications of gender. Cardiovascular Res 2002; 53: 538-549.

  27. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 1785-1790.

  28. Kannel WB, Dágostino RB, Belanger AJ: Fibrinogen, cigarrete smoking and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-1010.

  29. Cantin B, Despres JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, et al: Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002; 89: 662-666.

  30. Stout RW, Crawford V: Seasonal variations in fibrinogen concentrations among elderly people. Lancet 1991; 339: 9-13.

  31. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW: Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 345-349.

  32. Van del Bom J, De Maat M, Bots M, Hofman A, Kluyft C, Grobee D: Seasonal variation in fibrinogen in the Rotterdam study. Throm Haemost 1997; 78: 1059-1062.

  33. Rosenson RS, Mosca L, Staffileno BA, Tangney CC: Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. Atherosclerosis 2001; 159: 225-230.

  34. Folsom A, Wu K, Rosamond W, Sharret A, Chambless L: Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-1108.

  35. Chandler W, Rodgers GM, Sprouse JT, Thompson AR: Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002; 126: 1405-1414.

  36. Stec J, Silbershatz H, Tofler G, Matheney T, Sutherland P, Pipinska I, et al: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation 2000; 102: 1634-1638.




2020     |     www.medigraphic.com